Vumerity
Generic name:diroximel fumarate [ dye-ROX-i-mel-FUE-ma-rate ]
Drug class:Selective immunosuppressants
What is Vumerity?
Vumerity is a prescription medicine used to treat relapsing forms of multiple sclerosis in adults (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease).
Exactly how Vumerity works in treating multiple sclerosis is not known.
It is not known if Vumerity is safe and effective in children.
Warnings
You should not use Vumerity if you have had a severe allergic reaction to diroximel fumarate, or if you also use dimethyl fumarate (Tecfidera).
Before taking this medicine
You should not use Vumerity if:
you have had a severe allergic reaction to diroximel fumarate or dimethyl fumarate (Tecfidera); or
you also use dimethyl fumarate.
To make sure Vumerity is safe for you, tell your doctor if you have ever had:
kidney disease;
infections; or
low white blood cell (WBC) counts.
Tell your doctor if you are pregnant or breastfeeding.
Vumerity is not approved for use by anyone younger than 18 years old.
How should I take Vumerity?
Use Vumerity exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.
Your doctor will perform blood tests to make sure you do not have conditions that would prevent you from safely using Vumerity.
Swallow the capsule whole and do not crush, chew, break, or open it.
If you take Vumerity with food, avoid foods that are high in calories or fat. Your meal or snack should not contain more than 700 calories or more than 30 grams of fat.
Do not drink alcohol when you take your Vumerity dose.
Diroximel fumarate can lower your blood cell counts. You will need frequent medical tests, and your next dose may be delayed based on the results.
Store at room temperature away from moisture and heat.
Dosing information
Usual Adult Dose for Multiple Sclerosis:
Initial dose: 231 mg orally 2 times a day for 7 days, then increase to 462 mg orally 2 times a day
Maintenance dose: 462 mg orally 2 times a day; temporary dose reductions to 231 mg 2 times a day may be considered for individuals who do not tolerate the maintenance dose; within 4 weeks the recommended dose of 462 mg 2 times a day should be resumed; consider discontinuing therapy in patients unable to tolerate return to the maintenance dose
Comments:
-Administration of nonenteric coated aspirin (up to 325 mg) 30 minutes prior to this drug may reduce the incidence/severity
